HonCode

Go Back   HER2 Support Group Forums > Clinical Trials
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 01-26-2009, 03:22 PM   #1
julierene
Senior Member
 
julierene's Avatar
 
Join Date: Dec 2005
Location: Illinois
Posts: 327
Breast Cancer Vaccine at UAMC

Breast Cancer Research Development
4301 W. Markham St., #824
Little Rock, AR 72205-7199
501-526-5930
501-526-5934 (fax)
www.uams.edu/cancer

Thank you for contacting the Breast Team. We are expected to start clinical trials for our new vaccine in April 2009. The vaccine is on target to help prevent the recurrence of breast cancer. The vaccine was developed through a decade of studying how the immune system responds to disease. The peptide-based vaccine is designed to make the body think it's dealing with a carbohydrate which in turn tricks the body into producing antibodies that fight breast cancer cells. The immune system then responds by producing antibodies that target both the peptides in the vaccine and the carbohydrates they resemble on the breast cancer cells.

Dr. Laura Hutchins, director of the Division of Hematology and Oncology here at UAMS, is principal investigator for the clinical trial. The first phase of the clinical trial will last four to six months. It will involve women with metastatic cancer only, who have relapsed after going into remission. Women participating in the study will receive five doses of the vaccine at the Cancer Institute's Medical Oncology Clinic. They will be immunized once a week for the first three weeks and again during the seventh and 19th weeks. The first phase is to monitor any side effects of the vaccine.

We hope to begin the second phase of the clinical trial in January 2010. It will last a year and include women who have had breast cancer but are in remission and are considered at high risk of having it again. The women will have to have been off chemotherapy for at least six months. The number of patients participating in each study has not been determined. The first two studies will be done in Arkansas, but future clinical trials may expand to include patients from other cancer centers around the country.

The vaccine won't replace traditional cancer treatments such as chemotherapy and radiation. If you feel you fit the required description of a possible candidate for our trial, please contact us in April 2009. Thank you for your interest in the vaccine. To participate in the trial, you will need to be referred by your oncologist. The referral number is 501-296-1502, extension 1226. Please do not call before April, 2009, since your clinical status must be assessed immediately prior to registration. We are grateful for your interest in this research.
__________________
Jan04: Bilateral Mastectomy at age 28
Initial DX: Left Breast: IDC 2cm, Grade 3, HER2+3, 0 Nodes +, ER/PR-. Right Breast: Extensive DCIS ER-/PR+; Stage 1-2a
Feb04-Apr04: 4 AC, dose dense
Aug 04: 4 Taxotere
Dec 05: Bone and Liver METS; Stage 4. Carboplatin/Taxol/Herceptin. DX with Li-Fraumeni Syndrome
Apr 06: NED, maintenance Herceptin
Apr 07: CA1503=14; masses in liver; Xeloda/Tykerb
Nov 07: NED, Tykerb maintenance
Sept 08: Liver mets again, on Tykerb/Xeloda again, CA=19 and 27
Nov 08: Progression, Tykerb/Gemzar, CA=25
Dec 08: Progression, Herceptin/Navelbine, CA=40, 57, and 130
Jan 09: Progression in bone, recession in liver, Herceptin/Carbo/Abraxane CA=135
June 09: CA27/29=24, chemo break
Sept 09: Progression, CA=24, waiting on clinical trial (4 weeks no treatment)
Nov 09: now have brain mets, trial "on hold", getting 14 WBR treatments starting 11/2/09
Dec 09: possible start on p53 trial
julierene is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 07:02 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter